)
Lifeward (LFWD) investor relations material
Lifeward Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue for Q2 2026 increased 16% year-over-year to $6.6 million, the highest since Q4 2024, driven by strong AlterG and ReWalk sales, commercial execution, and improved average selling prices.
Strategic financing closed in July 2026 provided $5.6 million, with an additional $5.6 million available upon meeting certain milestones, strengthening the balance sheet with a proforma cash balance of $11 million.
Expanded distribution through a pilot with Ottobock Care and continued integration of recent acquisitions, including Oratech and Skelable.
Advanced clinical development of ORMD-0801 oral insulin, with Phase 2 trial preparations ongoing.
Board and executive transitions announced, including CFO departure effective September 30, 2026.
Financial highlights
Q2 2026 revenue: $6.6 million (up 16% year-over-year); ReWalk sales up 13% to $2.5 million, AlterG up 25% to $4.1 million; six-month revenue: $10.5 million (down 2% year-over-year due to Q1 supply constraints).
Gross margin for Q2 2026: 41% (Q2 2025: 44%), impacted by FX, tariffs, and revenue sharing expenses.
Net loss for Q2 2026: $11.5 million ($4.12/share), mainly due to non-cash fair value charges; adjusted net loss: $4.1 million ($1.46/share).
Cash and cash equivalents as of June 30, 2026: $9.4 million, up from $2.2 million at year-end 2025.
Operating expenses fell 24% to $6.9 million due to prior-year impairment charges; adjusted operating expenses rose 8% to $6.5 million.
Outlook and guidance
Growth expected from expanded reimbursement and coverage for ReWalk, increased AlterG shipments, new channel partnerships, and a strong sales pipeline.
Gross margin anticipated to improve as higher volumes drive better absorption of fixed costs and operational efficiencies.
Continued investment in R&D for product improvements and integration of acquired technologies.
Management expects ongoing operating losses and negative cash flows, with additional capital required to fund operations.
- Registering 2,066,662 shares for resale, with proceeds possible only from warrant exercises.LFWD
Registration filing - Revenue dropped 22% to $3.9M; net loss widened, but cash rose to $11.4M.LFWD
Q1 2026 - Registering 7.26M shares for resale after acquisitions, with no proceeds to the company.LFWD
Registration filing - 2025 revenue fell 14%, but unit sales, gross margin, and efficiency improved amid strategic expansion.LFWD
Q4 2025 - Shareholders to vote on acquisition, major share issuances, and board changes, enabling new growth.LFWD
Proxy Filing - Shareholders to vote on transformative acquisition, financings, and board changes, with major dilution.LFWD
Proxy Filing - Medical device firm seeks to raise $100M for growth via shelf offering of shares, warrants, and debt.LFWD
Registration Filing - Q3 revenue up 39% year-over-year, margins improved, and net loss narrowed to $3.1M.LFWD
Q3 2024 - Q2 revenue soared 400%+ to $6.7M, with Medicare and AlterG fueling growth and narrowed losses.LFWD
Q2 2024
Next Lifeward earnings date
Next Lifeward earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage